Molecular and General Genetics MGG

, Volume 252, Issue 5, pp 518–529 | Cite as

A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeastSchizosaccharomyces pombe

  • D. Casso
  • D. Beach
  • D. Casso
  • D. Beach
Original Paper

Abstract

A strong growth inhibition is observed when the human p53 tumor suppressor gene product is expressed in the fission yeastSchizosaccharomyces pombe. This growth inhibition is specific for wild-type p53; mutant alleles of p53 derived from human tumors show a greatly decreased ability to inhibit growth. These data suggest that there may be a p53-responsive pathway inS. pombe. To identify elements in this pathway genetically, we isolated a mutant yeast strain in which the growth inhibitory activity of p53 is largely suppressed. In addition, the activity of p53 as a transcription factor is also decreased in this strain. The suppression of p53 activity is not due to a decrease in p53 expression or a failure of p53 to localize to the nucleus. This p53 suppressor mutation is in a novelS. pombe gene with homology to thioredoxin reductase genes, and has been namedtrr1. Strains with a mutation of, or deletion in,trr1 are sensitive to oxidizing agents, suggesting that thetrr1 suppressor mutation causes partial loss oftrr1 function. Since oxidizing agents are able to suppress p53 activity in vitro, thistrr1 mutation may affect the activity of p53 in fission yeast by increasing the oxidation state of the tumor suppressor.

Key words

p53 Schizosaccharomyces pombe Thioredoxin reductase Redox state Transcriptional reporter 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altschul SF, Gish W, Miller W, Meyers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410PubMedGoogle Scholar
  2. Barak Y, Juven T, Haffner R, Oren M (1993)mdm-2 expression is induced by wild-type p53 activity. EMBO J 12:461–468PubMedGoogle Scholar
  3. Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C (1993) A proteolytic fragment from the central region of p53 has marked sequence-specific DNA binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 7:2565–2574PubMedGoogle Scholar
  4. Beach D, Rodgers L, Gould J (1985)ran1 + controls the transition from mitotic division to meiosis in fission yeast. Curr Genet 10:297–311PubMedGoogle Scholar
  5. Bischoff JR, Casso D, Beach D (1991) A yeast system to study human p53. In: Origins of human cancer: a comprehensive review. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, pp 51–63Google Scholar
  6. Bischoff JR, Casso D, Beach D (1992) Human p53 inhibits growth in the fission yeastSchizosaccharomyces pombe. Mol Cell Biol 12:1405–1411PubMedGoogle Scholar
  7. Booher RN, Beach D (1987) Interaction between cdc13+ and cdc2+ in the control of mitosis in fission yeast; dissociation of the G1 and G2 roles of the cdc2+ protein kinase. EMBO J 6:3441–3447PubMedGoogle Scholar
  8. Booher RN, Alpha CE, Hyams JS, Beach DH (1989) The fission yeast cdc2/cdc13/sucl protein kinase: regulation of catalytic activity and nuclear localization. Cell 58:485–497PubMedGoogle Scholar
  9. Caelles C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53 target genes. Nature 370:220–223PubMedGoogle Scholar
  10. Chae HZ, Chung SJ, Rhee SG (1994a) Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269:27670–27678PubMedGoogle Scholar
  11. Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG (1994b) Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Nat Acad Sci USA 91:7017–7021PubMedGoogle Scholar
  12. Cho YJ, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–355PubMedGoogle Scholar
  13. Cottarel G, Beach D, Deuschle U (1993) Two multipurpose multicopySchizosaccharomyces pombe vectors pSP1 and pSP2. Curr Genet 23:547–548PubMedGoogle Scholar
  14. Delphin C, Cahen P, Lawrence JJ, Baudier J (1994) Characterization of baculovirus recombinant wild-type p53. Dimerization of p53 is required for high affinity DNA binding and cysteine oxidation inhibits DNA binding. Eur J Biochem 223:683–692PubMedGoogle Scholar
  15. Demple B (1991) Regulation of bacterial oxidative stress genes. Annu Rev Genet 25:315–337PubMedGoogle Scholar
  16. Derman AI, Prinz WA, Belin D, Beckwith J (1993) Mutations that allow disulfide bond formation in the cytoplasm ofEscherichia coli. Science 262:1744–1747PubMedGoogle Scholar
  17. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Defining of a consensus binding site for p53. Nature Genet 1:45–49PubMedGoogle Scholar
  18. El-Deiry WS, Tokino T, Velculescu V, Levy D, Vogelstein B (1993) Waf-1: a potential mediator of p53 tumor suppression. Cell 75:817–825PubMedGoogle Scholar
  19. Field J, Nikawa JI, Broek D, MacDonald B, Rodgers L, Wilson IA, Lerner RA, Wigler M (1988) Purification of a RAS-responsive adenylyl cyclase complex fromSaccharomyces cerevisiae by use of an epitope addition method. Mol Cell Biol 8:2159–2165PubMedGoogle Scholar
  20. Fields S, Jang SK (1990) Presence of a potent transcriptional activating sequence in the p53 protein. Science 249:1046–1049PubMedGoogle Scholar
  21. Fornace AJ, Alamo IJ, Hollander MC (1988) DNA damage-inducible transcripts in mammalian cells. Proc Natl Acad Sci USA 85:8800–8804PubMedGoogle Scholar
  22. Forsburg SL, Guarente L (1988) Mutational analysis of upstream activation sequence 2 of theCYC1 gene ofSaccharomyces cerevisiae: aHAP2-HAP3-responsive site. Mol Cell Biol 8:647–654PubMedGoogle Scholar
  23. Friend S (1994) p53: a glimpse at the puppet behind the shadow play. Science 265:334–335PubMedGoogle Scholar
  24. Gannon JV, Lane DP (1991) Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349:802–805PubMedGoogle Scholar
  25. Ginsberg D, Mechta F, Yaniv M, Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA 88:9979–9983PubMedGoogle Scholar
  26. Gutz H, Heslot H, Leupold U, Loprieno N (1974)Schizosaccharomyces pombe. In: King RC (ed) Handbook of genetics, vol. 1. Plenum Publishing, New York, pp 395–446Google Scholar
  27. Haffner R, Oren M (1995) Biochemical properties and biological effects of p53. Curr Biol 5:84–90Google Scholar
  28. Hainault P, Milner J (1993a) Redox modulation of p53 conformation and sequence-specific DNA binding. Cancer Res 53:4469–4473PubMedGoogle Scholar
  29. Hainault P, Milner J (1993b) A structural role for metal ions in the “wild-type” conformation of the tumor suppressor protein p53. Cancer Res 53:1739–1742PubMedGoogle Scholar
  30. Hannon GJ, Casso D, Beach D (1994) KAP: a dual-specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci USA 91:1731–1735PubMedGoogle Scholar
  31. Harlow E, Crawford LV, Pim PC, Williamson NM (1981) Monoclonal antibodies specific for simian virus 40 tumor antigen. J Virol 39:861–869PubMedGoogle Scholar
  32. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 cdk-interacting protein Cip-1 is a potent inhibitor of G1 cyclin dependent kinases. Cell 75:805–816PubMedGoogle Scholar
  33. Holmgren A (1989) Thioredoxin and glutaredoxin systems. J Biol Chem 264:13693–13766PubMedGoogle Scholar
  34. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S (1994) Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 91:6098–6102PubMedGoogle Scholar
  35. Jayaraman L, Prives C (1995) Activation of p53 sequence-specific binding by short single stands of DNA requires the p53 C-terminus. Cell 81:1021–1031PubMedGoogle Scholar
  36. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BV, Vogelstein, Fornace AJ (1992) A mammalian cell cycle check point pathway utilizing p53 and GADD45 is defective in ataxia-telangectasia. Cell 71:587–597PubMedGoogle Scholar
  37. Lane DP (1994) p53 and human cancers. Brit Med Bull 50:582–599PubMedGoogle Scholar
  38. Leupold U (1970) Genetic methods forSchizosaccharomyces pombe. Methods Cell Physiol 4:169–177Google Scholar
  39. Lee S, Elenbaas B, Levine A, Griffith J (1995) p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013–1020PubMedGoogle Scholar
  40. Lowndes NF, McInery CJ, Johnson AL, Fantes PA, Johnston LH (1992) Control of DNA synthesis genes in fission yeast by the cell cycle genecdc10 +. Nature 355:449–453PubMedGoogle Scholar
  41. Maltzman W, Czyzyk L (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4:1689–1694PubMedGoogle Scholar
  42. Martin DW, Munoz RM, Subler MA, Deb S (1993) p53 binds the TATA-binding protein-TATA complex. J Biol Chem 268:13062–13067PubMedGoogle Scholar
  43. Martinez J, Georgoff I, Martinez J, Levine AJ (1991) Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5:151–159PubMedGoogle Scholar
  44. Maundrell K (1993) Thiamine-repressible vectors pREP and pRIP for fission yeast. Gene 123:127–130PubMedGoogle Scholar
  45. Maundrell K (1990)nmt1 of fission yeast: a highly transcribed gene completely repressed by thiamine. J Biol Chem 265:10857–10864PubMedGoogle Scholar
  46. Mitomo K, Nakayama K, Fujimoto K, Sun X, Seki S, Yamamoto K (1994) Two different cellular redox systems regulate the DNA-binding activity of the p50 subunit of NF-kappa B in vitro. Gene 145:197–203PubMedGoogle Scholar
  47. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the humanbax gene. Cell 80:293–299PubMedGoogle Scholar
  48. Mizukami T, Chang WI, Garkavtsev I, Kaplan N, Lombardi D, Matsumoto T, Niwa O, Kounosu A, Yanagiga M, Marr TG, Beach D (1993) A 13 kb resolution cosmid map of the 14 Mb fission yeast genome by nonrandom sequence-tagged site mapping. Cell 73:121–132PubMedGoogle Scholar
  49. Moll UM, Riou G, Levine AJ (1992) Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 89:7262–7266PubMedGoogle Scholar
  50. Muller EGD (1994) Deoxyribonucleotides are maintained at normal levels in a yeast thioredoxin mutant defective in DNA synthesis. J Biol Chem 269:24466–24471PubMedGoogle Scholar
  51. Nakanishi N, Yamamoto M (1984) Analysis of the structure and transcription of thearo3 gene cluster inSchizosaccharomyces pombe. Mol Gen Genet 195:164–169PubMedGoogle Scholar
  52. Nigro JM, Sikorski R, SI Reed SI, Vogelstein B (1992) Human p53 and CDC2Hs genes combine to inhibit the proliferation ofSaccharomyces cerevisiae. Mol Cell Biol 12:1357–1365PubMedGoogle Scholar
  53. Okamoto K, Beach D (1994) Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13:4816–4822PubMedGoogle Scholar
  54. Okazaki K, Okazaki N, Kume S, Jinno S, Tanaka K, Okayama H (1990) High-frequency transformation method and library-transducing vectors for cloning mammalian cDNAs by transcomplementation inSchizosaccharomyces pombe. Nucleic Acids Res 18:6485PubMedGoogle Scholar
  55. Okuno H, Akahori A, Sato H, Xanthoudakis S, Curran T, Iba H (1992) Escape from redox regulation enhances the transforming activity offos. Oncogene 7:695–701Google Scholar
  56. Raycroft L, Wu H, Lozano G (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051PubMedGoogle Scholar
  57. Russel M, Model P, Holmgren A (1990) Thioredoxin or glutaredoxin in Escherichia coli is essential for sulfate reduction but not for deoxyribonucleotide synthesis. J Bacteriol 172:1923–1929PubMedGoogle Scholar
  58. Russell P (1989) Gene cloning and expression in fission yeast. In: Nasim A, Young P, Johnson BF (eds) Molecular biology of the fission yeast. Academic Press, New York, pp 244–271Google Scholar
  59. Scharer E, Iggo R (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res 20:1539–1545PubMedGoogle Scholar
  60. Shaulsky G, Ben-Ze'ev A, Rotter V (1990) Nuclear accumulation of p53 is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 10:6567–6577Google Scholar
  61. Soussi T, deFromental CC, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945–952PubMedGoogle Scholar
  62. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B (1994) Multifactorial analysis of p53 altertion in human cancer: a review. Int J Cancer 57:1–9PubMedGoogle Scholar
  63. Thut C, Chen J-L, Klemm R, Tjian R (1995) p53 transcriptional activation mediated by coactivators TAFII40, and TAFII60. Science 267:100–104PubMedGoogle Scholar
  64. Toledano MB, Kullik I, Trinh F, Baird PT, Schneider TD, Storz G (1994) Redox-dependent shift of OxyR-DNA contacts along an extended DNA binding site: a mechanism for different promoter selection. Cell 78:897–909PubMedGoogle Scholar
  65. Truant R, Xiao H, Ingles CJ, Greenblatt J (1993) Direct interaction between the transactivation domain of human p53 and the TATA binding protein. J Biol Chem 268:2284–2287PubMedGoogle Scholar
  66. Uemura T, Yanagidal M (1984) Isolation of type I and type II topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization. EMBO J 3:1737–1744PubMedGoogle Scholar
  67. Wagner P, Simanis V, Maimets T, Keenan E, Addison C, Brain R, Grimaldi M, Sturzbecher HW, Jenkins J (1991) A human tumorderived mutant p53 protein induces a p34cdc2-reversible growth arrest in fission yeast. Oncogene 6:1539–1547PubMedGoogle Scholar
  68. Wagner P, Grimaldi M, Jenkins JR (1993) Putative dehydrogenase tms1 suppresses growth arrest induced by a p53 tumor mutant in fission yeast. Eur J Biochem 217:731–736PubMedGoogle Scholar
  69. Wu X, Bayle JH, Olson D, Levine AJ (1993) The p53-mdm-2 autoregulatory feedback loop. Genes Dev 7:1126–1132PubMedGoogle Scholar
  70. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6 Nature 352:345–347PubMedGoogle Scholar
  71. Zhang MQ, Marr TG (1994) Fission yeast gene structure and recognition. Nucleic Acids Res 22:1750–1759PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • D. Casso
    • 1
  • D. Beach
    • 1
  • D. Casso
    • 2
  • D. Beach
    • 2
  1. 1.Cold Spring Harbor LaboratoryHoward Hughes Medical InstituteCold Spring Harbor
  2. 2.Graduate Program in Molecular and Cellular BiologyState University of New YorkStony Brook

Personalised recommendations